John M. Keane
the Board appointed as a director of the Company General John M. “Jack” Keane (Ret.), effective immediately
Highest-materiality recent filing
SIGA Q2 2026 revenue drops 49% YoY to $41M; EPS $0.17 vs $0.49
Product sales $37.9M in Q2 2026, down from $79.1M in Q2 2025; total revenues $41.0M vs $81.1M.
SIGA Q1 net loss widens to $3.5M; revenue falls to $6.2M
Product sales $3.5M vs $5.8M YoY; total revenue $6.2M vs $7.0M.
SIGA declares special $0.60/share dividend payable April 23
Special one-time cash dividend of $0.60 per common share declared.
SIGA 2025 product revenue $88M, down 34% YoY; net income $23.3M vs $59.2M
Product revenues of $88M in 2025, down from $133M in 2024; total revenues $94.6M.
SIGA reports Q3 2025 net loss of $6.4M on $2.6M revenue, down from $1.3M income YoY
Q3 2025 product sales fell to $0.9M from $8.9M YoY; total revenue $2.6M vs $10.0M.
SIGA reports Q2 2025 product revenues $79.1M, net income $35.5M, EPS $0.49; new BARDA funding $27M
Record quarterly total revenue of $195.5M, up 29.4% from $151.1M in Q2 2024, including $79.1M product sales
SIGA Q1 2025 net loss $0.4M, revenue $7.0M; special dividend $0.60
Q1 2025 total revenues $7.0M (down 72% YoY); net loss $0.4M ($0.01 EPS) vs net income $10.3M ($0.14 EPS) in Q1 2024.
SIGA declares special one-time dividend of $0.60/share payable May 15, 2025
Special one-time cash dividend of $0.60 per share declared on April 8, 2025.
SIGA FY2024 net income $59.2M ($0.82 EPS); product sales $133M, up 2% YoY
Product sales were $133M in 2024 vs $130.7M in 2023, including $100M to US SNS.
SIGA's tecovirimat fails mpox lesion resolution endpoint; STOMP enrollment stopped
Tecovirimat did not improve time to lesion resolution vs placebo in mild to moderate clade II mpox; DSMB recommended stop enrollment.
SIGA reports Q3 product revenues $8.9M; receives $122M in procurement orders from US government
Product revenues $8.9M (Q3 2024) vs $8.0M YoY; total revenues $10.0M.
SIGA Technologies CMO and Board Member Jay Varma begins indefinite leave
Dr. Jay K. Varma commenced indefinite leave as EVP, Chief Medical Officer and board member on Sept 19, 2024.
SIGA's tecovirimat misses primary endpoint in PALM 007 mpox trial; shows benefit in subgroups
PALM 007 did not meet primary endpoint of statistically significant improvement in time to lesion resolution.
SIGA Q2 product sales $20.7M, net income $1.8M; receives $113M U.S. order in July
Product sales $20.7M in Q2 (vs $1.3M prior year); total revenues $21.8M; net income $1.8M or $0.03 diluted EPS.
SIGA receives $113M US government procurement order for oral TPOXX
U.S. HHS exercised procurement option for ~$113M of oral TPOXX treatment courses under current contract.
SIGA Q1 2024: product sales $23.9M, net income $10.3M, $0.60 special dividend
Product sales $23.9M vs $5.7M YoY; total revenues $25.4M vs $8.3M.
Product sales increased 51% YoY to $130.7M (including supportive services) for the year ended Dec 31, 2023.
SIGA appoints Diem Nguyen as CEO effective Jan 27, 2024; Phil Gomez retires
Diem Nguyen appointed CEO and board member effective Jan 27, 2024; Phil Gomez retires Jan 26.
SIGA extends CEO Gomez's transition to March 31, 2024 as successor search continues
CEO Phillip Louis Gomez III will remain CEO until March 31, 2024, or earlier upon successor's start.
SIGA Q3 revenue $9.2M, net loss $0.4M; guides FY pre-tax income $90-100M on Q4 deliveries
Q3 2023 total revenue $9.2M, down from $72.2M YoY; net loss $0.4M vs net income $33.0M.
Q2 total revenues $5.9M, down from $16.7M YoY; net loss $2.9M vs net income $2.0M; diluted EPS -$0.04.
U.S. Government exercises ~$138M procurement options for oral and IV TPOXX from SIGA
BARDA contract options exercised: ~$113M oral TPOXX (delivery in 2023) and ~$25M IV TPOXX (delivery starts 2024).
SIGA declares special $0.45/share cash dividend payable June 1, 2023
Special cash dividend of $0.45 per share declared by the Board of Directors.
SIGA reports FY2022 revenue $110.8M, net income $33.9M; international sales surge to $71M
FY2022 total revenues $110.8M (down from $133.7M in 2021); net income $33.9M ($0.46 diluted EPS vs $0.91).
SIGA Technologies CEO Phil Gomez plans 2023 retirement; board launches CEO search
CEO Phil Gomez announced retirement in 2023; will remain CEO until successor starts.
SIGA Q3 2022 revenue surges to $72.2M from $4.8M YoY; net income of $33.0M vs loss
Q3 2022 total revenues $72.2M, compared to $4.8M in Q3 2021; net income $33.0M ($0.45 diluted EPS).
SIGA receives BARDA $26M procurement option exercise for IV TPOXX; deliveries targeted for 2023
BARDA exercises procurement options valued at approximately $26M for IV TPOXX under contract 19C.
SIGA Q2 revenue $16.7M (+92% YoY); special dividend; director resigns
Q2 revenue $16.7M (up 92% YoY); net income $2.0M, diluted EPS $0.03 vs ($0.00).
SIGA announces ~$28M in international orders for oral TPOXX amid monkeypox outbreak
Orders include $26M from Canada (PHAC & DND) and $2M from two new jurisdictions (Europe, Asia Pacific).
SIGA declares special cash dividend of $0.45 per share
Special dividend of $0.45 per share, payable June 2, 2022.
SIGA Q1 revenue doubles to $10.5M; net loss narrows; declares special $0.45 dividend
Q1 total revenues $10.5M vs $4.8M YoY; operating loss improved to $1.4M from $2.0M.
SIGA reports 2021 revenue $133.7M, net income $69.5M; EPS $0.91; EMA approves TPOXX
FY2021 total revenues $133.7M; net income $69.5M ($0.91 diluted EPS) vs $56.3M ($0.71) in FY2020.
SIGA reports Q3 revenue drop to $4.8M, net loss of $3.1M; secures $113M BARDA order for Q4
Total revenues $4.8M in Q3 2021 vs $44.3M in Q3 2020; net loss $3.1M ($0.04 diluted loss) vs net income $24.2M ($0.31 diluted EPS).
the Board appointed as a director of the Company General John M. “Jack” Keane (Ret.), effective immediately
Pursuant to the terms of his employment agreement, Dr. Varma’s service on the Company’s Board of Directors also automatically ended effective immediately.
On September 23, 2024, the Board of Directors of SIGA Technologies, Inc. (the “Company”) terminated Dr. Jay Varma, effective immediately, other than for cause, from his position as Executive Vice President and Chief Medical Officer of the Company.
On September 19, 2024, Dr. Jay K. Varma began an indefinite leave of absence from his positions as Executive Vice President and Chief Medical Officer of SIGA Technologies, Inc. (the “Company”) and as a member of the Board of Directors of the Company.
On September 19, 2024, Dr. Jay K. Varma began an indefinite leave of absence from his positions as Executive Vice President and Chief Medical Officer of SIGA Technologies, Inc. (the “Company”) and as a member of the Board of Directors of the Company.
On January 22, 2024, SIGA Technologies, Inc. (the “Company”) announced the appointment of Diem Nguyen, Ph.D., MBA, as Chief Executive Officer of the Company and a member of the Company’s Board of Directors, in each case, effective as of January 27, 2024
On September 6, 2023, SIGA Technologies, Inc. (the “Company”) issued a press release announcing the appointment of Dr. Jay K. Varma as Executive Vice President and Chief Medical Officer of the Company.
Dr. Gomez will continue to serve as Chief Executive Officer of the Company until the earlier of (A) January 1, 2024, or (B) the date a new Chief Executive Officer commences services with the Company in such role
On January 13, 2023, Phillip Gomez provided notice to SIGA Technologies, Inc. (the “Company”) of his intent to retire as Chief Executive Officer of the Company in 2023 and to resign from the Board of Directors (the “Board”) when he ceases to serve as Chief Executive Officer.
the Board appointed Harold Ford and Jay Varma, MD as directors of the Company, effective immediately.
the Board appointed Harold Ford and Jay Varma, MD as directors of the Company, effective immediately.
On July 31, 2022, James Antal provided notice to the Company of his resignation from the Board of Directors of the Company, effective immediately, due to personal health reasons.
Max materiality 0.85 · Median 0.65 · Most common event earnings